Literature DB >> 27488532

The Genomic Landscape of Pancreatic and Periampullary Adenocarcinoma.

Vandana Sandhu1, David C Wedge2, Inger Marie Bowitz Lothe3, Knut Jørgen Labori4, Stefan C Dentro2, Trond Buanes5, Martina L Skrede6, Astrid M Dalsgaard6, Else Munthe7, Ola Myklebost7, Ole Christian Lingjærde8, Anne-Lise Børresen-Dale9, Tone Ikdahl10, Peter Van Loo11, Silje Nord6, Elin H Kure12.   

Abstract

Despite advances in diagnostics, less than 5% of patients with periampullary tumors experience an overall survival of five years or more. Periampullary tumors are neoplasms that arise in the vicinity of the ampulla of Vater, an enlargement of liver and pancreas ducts where they join and enter the small intestine. In this study, we analyzed copy number aberrations using Affymetrix SNP 6.0 arrays in 60 periampullary adenocarcinomas from Oslo University Hospital to identify genome-wide copy number aberrations, putative driver genes, deregulated pathways, and potential prognostic markers. Results were validated in a separate cohort derived from The Cancer Genome Atlas Consortium (n = 127). In contrast to many other solid tumors, periampullary adenocarcinomas exhibited more frequent genomic deletions than gains. Genes in the frequently codeleted region 17p13 and 18q21/22 were associated with cell cycle, apoptosis, and p53 and Wnt signaling. By integrating genomics and transcriptomics data from the same patients, we identified CCNE1 and ERBB2 as candidate driver genes. Morphologic subtypes of periampullary adenocarcinomas (i.e., pancreatobiliary or intestinal) harbor many common genomic aberrations. However, gain of 13q and 3q, and deletions of 5q were found specific to the intestinal subtype. Our study also implicated the use of the PAM50 classifier in identifying a subgroup of patients with a high proliferation rate, which had impaired survival. Furthermore, gain of 18p11 (18p11.21-23, 18p11.31-32) and 19q13 (19q13.2, 19q13.31-32) and subsequent overexpression of the genes in these loci were associated with impaired survival. Our work identifies potential prognostic markers for periampullary tumors, the genetic characterization of which has lagged. Cancer Res; 76(17); 5092-102. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2016        PMID: 27488532     DOI: 10.1158/0008-5472.CAN-16-0658

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  13 in total

1.  Upregulation of DLC-1 inhibits pancreatic cancer progression: Studies with clinical samples and a pancreatic cancer model.

Authors:  Bo Chen; Mingzheng Xu; Ming Xu
Journal:  Oncol Lett       Date:  2019-09-16       Impact factor: 2.967

Review 2.  Low-Molecular-Weight Cyclin E in Human Cancer: Cellular Consequences and Opportunities for Targeted Therapies.

Authors:  Joseph A Caruso; Mylinh T Duong; Jason P W Carey; Kelly K Hunt; Khandan Keyomarsi
Journal:  Cancer Res       Date:  2018-09-07       Impact factor: 12.701

Review 3.  Systems Oncology: Bridging Pancreatic and Castrate Resistant Prostate Cancer.

Authors:  A Fucic; A Aghajanyan; Z Culig; N Le Novere
Journal:  Pathol Oncol Res       Date:  2018-09-16       Impact factor: 3.201

4.  Patient-derived tumor xenograft and organoid models established from resected pancreatic, duodenal and biliary cancers.

Authors:  Nhu-An Pham; Nikolina Radulovich; Emin Ibrahimov; Sebastiao N Martins-Filho; Quan Li; Melania Pintilie; Jessica Weiss; Vibha Raghavan; Michael Cabanero; Robert E Denroche; Julie M Wilson; Cristiane Metran-Nascente; Ayelet Borgida; Shawn Hutchinson; Anna Dodd; Michael Begora; Dianne Chadwick; Stefano Serra; Jennifer J Knox; Steven Gallinger; David W Hedley; Lakshmi Muthuswamy; Ming-Sound Tsao
Journal:  Sci Rep       Date:  2021-05-19       Impact factor: 4.379

5.  Survival Benefit of Adjuvant Chemotherapy After Pancreatoduodenectomy for Ampullary Adenocarcinoma: a Propensity-Matched National Cancer Database (NCDB) Analysis.

Authors:  Sivesh K Kamarajah; Filip Bednar; Clifford S Cho; Hari Nathan
Journal:  J Gastrointest Surg       Date:  2020-11-23       Impact factor: 3.452

Review 6.  Updated therapeutic outcome for patients with periampullary and pancreatic cancer related to recent translational research.

Authors:  Trond A Buanes
Journal:  World J Gastroenterol       Date:  2016-12-28       Impact factor: 5.742

7.  A novel hotspot and rare somatic mutation p.A138V, at TP53 is associated with poor survival of pancreatic ductal and periampullary adenocarcinoma patients.

Authors:  Gourab Saha; Richa Singh; Argha Mandal; Subrata Das; Esita Chattopadhyay; Prasun Panja; Paromita Roy; Navonil DeSarkar; Sumit Gulati; Supriyo Ghatak; Shibajyoti Ghosh; Sudeep Banerjee; Bidyut Roy; Saurabh Ghosh; Dipankar Chaudhuri; Neeraj Arora; Nidhan K Biswas; Nilabja Sikdar
Journal:  Mol Med       Date:  2020-06-17       Impact factor: 6.354

8.  Genome-wide profiling of circulating tumor DNA depicts landscape of copy number alterations in pancreatic cancer with liver metastasis.

Authors:  Tao Wei; Jian Zhang; Jin Li; Qi Chen; Xiao Zhi; Wei Tao; Jingjiao Ma; Jiaqi Yang; Yu Lou; Tao Ma; Xiang Li; Qi Zhang; Wei Chen; Risheng Que; Shunliang Gao; Xueli Bai; Tingbo Liang
Journal:  Mol Oncol       Date:  2020-07-15       Impact factor: 6.603

9.  MetaGxData: Clinically Annotated Breast, Ovarian and Pancreatic Cancer Datasets and their Use in Generating a Multi-Cancer Gene Signature.

Authors:  Deena M A Gendoo; Michael Zon; Vandana Sandhu; Venkata S K Manem; Natchar Ratanasirigulchai; Gregory M Chen; Levi Waldron; Benjamin Haibe-Kains
Journal:  Sci Rep       Date:  2019-06-19       Impact factor: 4.379

10.  Apparent diffusion coefficient-based histogram analysis differentiates histological subtypes of periampullary adenocarcinoma.

Authors:  Jing-Yu Lu; Hao Yu; Xian-Lun Zou; Zhen Li; Xue-Mei Hu; Ya-Qi Shen; Dao-Yu Hu
Journal:  World J Gastroenterol       Date:  2019-10-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.